Vifor Pharma shares soar on CSL bid talk

Media reports overnight from Australia said the biotech giant was looking at an equity raise to help fund any purchase.

Vifor makes treatments for iron deficiency and chronic kidney disease. CSL was reported to be part way through due diligence, having already had a detailed look at the company about six months ago.

The Australian Financial Review cited unnamed sources as saying a deal “could be a few weeks away”.

Both Vifor Pharma and CSL declined to comment on the reports.